Loading...
Market
How many new global markets will approve Tagrisso for stage III EGFR+ NSCLC by end of 2024?
5
Resolution / Starting Odds
0 to 2 • 25%
3 to 5 • 25%
6 to 8 • 25%
More than 8 • 25%
AstraZeneca's official announcements and international regulatory agencies
Story
AstraZeneca's Tagrisso Shows Major PFS Benefit (HR=0.16) in Stage III Lung Cancer Laura Trial
Jun 2, 2024, 12:56 PM
At the ASCO 2024 conference, AstraZeneca reported significant findings regarding its drug Tagrisso and its impact on stage III non-small cell lung cancer (NSCLC) with EGFR mutations. The Laura trial demonstrated a massive progression-free survival (PFS) benefit with a hazard ratio of 0.16. However, the study noted an 81% rate of placebo patient crossover, effectively making it a comparison of maintenance Tagrisso versus Tagrisso on progression. Osimertinib could alter the standard of care (SOC) for stage III EGFR+ NSCLC, according to Dr. Ramalingam. These findings highlight the potential of targeted therapies in improving cancer treatment outcomes.
View original story
Similar markets
Less than 20 • 33%
20 to 40 • 33%
More than 40 • 34%
Less than 20% • 33%
20% to 40% • 33%
Greater than 40% • 34%
Less than $500 million • 33%
$500 million to $1 billion • 33%
Greater than $1 billion • 34%
0 countries • 20%
1-3 countries • 20%
4-6 countries • 20%
7-9 countries • 20%
10 or more countries • 20%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
Less than 5 • 25%
5 to 9 • 25%
10 to 14 • 25%
15 or more • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
More than 30 countries • 25%